NYSEAMERICAN:ISRIsoRay Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IsoRay.

IsoRay is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020. View our earnings forecast for IsoRay.

IsoRay, Inc. (NYSEAMERICAN:ISR) announced its earnings results on Tuesday, May, 12th. The healthcare company reported ($0.01) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.01). The healthcare company had revenue of $2.88 million for the quarter, compared to analyst estimates of $2.76 million. View IsoRay's earnings history.

2 analysts have issued twelve-month price objectives for IsoRay's shares. Their forecasts range from $1.25 to $1.75. On average, they expect IsoRay's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 167.9% from the stock's current price. View analysts' price targets for IsoRay.

Media coverage about ISR stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. IsoRay earned a news impact score of -1.3 on InfoTrie's scale. They also gave headlines about the healthcare company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about IsoRay.

IsoRay saw a decline in short interest in June. As of June 15th, there was short interest totaling 2,170,000 shares, a decline of 12.9% from the May 31st total of 2,490,000 shares. Based on an average trading volume of 488,600 shares, the days-to-cover ratio is currently 4.4 days. Currently, 3.3% of the company's shares are short sold. View IsoRay's Current Options Chain.

Some companies that are related to IsoRay include Retractable Technologies (RVP), CRH Medical (CRHM), CRH Medical (CRHM), SDI (SDI), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), TransEnterix (TRXC), Akers Biosciences (AKR), Relevium Technologies (RLV) and Vigil Health Solutions (VGL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IsoRay investors own include Brainstorm Cell Therapeutics (BCLI), Opko Health (OPK), Bausch Health Companies (BHC), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), MannKind (MNKD), TherapeuticsMD (TXMD), Anavex Life Sciences (AVXL), Plug Power (PLUG) and Catalyst Pharmaceuticals (CPRX).

IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ISR stock can currently be purchased for approximately $0.56.

IsoRay has a market capitalization of $37.88 million. IsoRay employs 38 workers across the globe.

The official website for IsoRay is isoray.com.

IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.